이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Novogene 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Ruiqiang Li

최고 경영자

CN¥417.3k

총 보상

CEO 급여 비율	n/a
CEO 임기	5yrs
CEO 소유권	52.0%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	2yrs

최근 관리 업데이트

Recent updates

Some Confidence Is Lacking In Novogene Co., Ltd. (SHSE:688315) As Shares Slide 26%

Jun 07

Time To Worry? Analysts Are Downgrading Their Novogene Co., Ltd. (SHSE:688315) Outlook

Apr 17

Estimating The Fair Value Of Novogene Co., Ltd. (SHSE:688315)

Mar 25

CEO

Ruiqiang Li (44 yo)

5yrs

테뉴어

CN¥417,300

보상

Dr. Li Ruiqiang is Founder of Novogene Co., Ltd. Dr. Ruiqiang serves as Chairman of the Board and Chief Executive Officer at Novogene Co., Ltd. and serves as its Director since June 15, 2019 Dr. Ruiqiang i...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Ruiqiang Li	Founder	5yrs	CN¥417.30k	52.02% CN¥ 2.3b
Ping Li	Supervisor	2yrs	데이터 없음	데이터 없음
Chunfei Wang	Independent Director	2yrs	데이터 없음	데이터 없음
Quan Gan	Director	2yrs	데이터 없음	데이터 없음

2.0yrs

평균 재임 기간

44yo

평균 연령

경험이 풍부한 이사회: 688315 의 이사회는 경험(평균 재직 기간 2 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Novogene 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Novogene Co., Ltd., Annual General Meeting, May 06, 2024

Recent updates

Some Confidence Is Lacking In Novogene Co., Ltd. (SHSE:688315) As Shares Slide 26%

Time To Worry? Analysts Are Downgrading Their Novogene Co., Ltd. (SHSE:688315) Outlook

First quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.06 in 1Q 2023)

Now 21% undervalued after recent price drop

Novogene Co., Ltd., Annual General Meeting, May 06, 2024

Novogene Co., Ltd. to Report Q1, 2024 Results on Apr 13, 2024

Estimating The Fair Value Of Novogene Co., Ltd. (SHSE:688315)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Novogene Co., Ltd. (SHSE:688315) announces an Equity Buyback for CNY 160 million worth of its shares.

Investor sentiment deteriorates as stock falls 17%

Now 20% overvalued

New minor risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.14 in 3Q 2022)

Investor sentiment deteriorates as stock falls 16%

Consensus EPS estimates fall by 13%

Novogene Co., Ltd. to Report First Half, 2023 Results on Aug 01, 2023

First quarter 2023 earnings released: EPS: CN¥0.06 (vs CN¥0.07 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.58 in FY 2021)

Novogene Announces Deployment of Illumina NovaSeq™ X Plus and PacBio REVIO Sequencing Systems

Investor sentiment improved over the past week

Price target decreased to CN¥28.89

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 3Q 2021)

Investor sentiment deteriorated over the past week

Novogene America Unveils Superpowered Robot Scientist for Autonomously Intelligent NGS Delivery- Falcon II

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.087 (vs CN¥0.13 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Now 25% undervalued after recent price drop

Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.07 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.037 loss in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.17 loss in 1Q 2020)

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령